3.80

5.26% 0.19

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $3.80, with a volume of 4.93M. It is up +5.26% in the last 24 hours and down -43.79% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Previous Close:

$3.61

Open:

$3.61

24h Volume:

4.93M

Relative Volume:

2.30

Market Cap:

$253.21M

Revenue:

$80.00M

Net Income/Loss:

$-76.12M

P/E Ratio:

-3.3144

EPS:

-1.1465

Net Cash Flow:

$-63.88M

1W Performance:

+2.70%

1M Performance:

-43.79%

6M Performance:

-67.18%

1Y Performance:

-48.51%

1-Day Range:

$3.55

$3.83

1-Week Range:

$3.55

$4.015

52-Week Range:

$2.83

$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (615)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2026-08-04

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	3.80	253.21M	80.00M	-76.12M	-63.88M	-1.1465
VRTX Vertex Pharmaceuticals Inc	491.34	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Initiated	JP Morgan	Overweight
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

05:31 AM

Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

05:31 AM

Jun 26, 2026

[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan

Jun 26, 2026

Jun 25, 2026

EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan

Jun 25, 2026

EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan

Jun 25, 2026

Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks

Jun 25, 2026

Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan

Jun 25, 2026